title: CHO expressed recombinant human lactoferrin as an adjuvant for BCG.
abstract: Lactoferrin (LF), an iron binding protein with immune modulatory activities, has adjuvant activity to enhance vaccine efficacy. Tuberculosis (TB) is a pulmonary disease caused by the pathogen Mycobacterium tuberculosis (MTB). Progressive TB disease is clinically defined by damaging pulmonary pathology, a result of inflammation due to immune reactivity. The current vaccine for TB, an attenuated strain of Mycobacterium bovis, Bacillus Calmette Guerin (BCG), has only limited efficacy to prevent adult pulmonary TB. This study examines a Chinese hamster ovary (CHO) expressed recombinant human LF (rHLF) to boost efficacy of the BCG vaccine and delay early pathology post infectious challenge. C57BL/6 mice were immunized with BCG, or BCG admixed with either rHLF or bovine LF (bLF; internal control), or remained unvaccinated. Mice were then aerosol challenged with Erdman MTB. All vaccinated mice demonstrated decreased organ bacterial load up to 19 weeks post infection compared with non-vaccinated controls. Furthermore, mice receiving bLF or rHLF supplemented BCG vaccines showed a modest decrease in lung pathology developed over time, compared to the BCG vaccine alone. While mice vaccinated with BCG/rHLF demonstrated increased general lung inflammation at day 7, it occurred without noticeable increase in pro-inflammatory cytokines. At later times, decreased pathology in the rHLF groups correlated with decreased inflammatory cytokines. Splenic recall to BCG antigens showed BCG/rHLF vaccination increased production of IFN-γ, IL-6, and GM-CSF compared to naïve, BCG, and BCG/bLF groups. Analysis of T cell stimulating functions of bone marrow derived macrophages and dendritic cells treated with BCG/bLF or BCG/rHLF showed decreases in IL-10 production when co-cultured with sensitized CD4 and CD8 T cells, compared to those cultured with macrophages/dendritic cells treated with BCG without LF. These results indicate that addition of rHLF to the BCG vaccine can modulate development of host pathology early post infectious challenge, most likely through host immune regulation affecting hypersensitive responses.
authors: Department of Pathology, Medical School, University of Texas-Houston Medical School, Houston, TX, USA.
authors: Shen-An
authors: SA
authors: Hwang
authors: Department of Integrative Biology and Pharmacology, University of Texas-Houston Medical School, Houston, TX, USA.
authors: Marian L
authors: ML
authors: Kruzel
authors: Department of Pathology, Medical School, University of Texas-Houston Medical School, Houston, TX, USA Jeffrey.K.Actor@uth.tmc.edu.
authors: Jeffrey K
authors: JK
authors: Actor
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D001500:BCG Vaccine / Q000276:immunology*; D016466:CHO Cells; D003412:Cricetulus; D016207:Cytokines / Q000502:physiology; D005260:Female; D007781:Lactoferrin / Q000096:biosynthesis* / Q000494:pharmacology; D008168:Lung / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D011994:Recombinant Proteins / Q000096:biosynthesis* / Q000494:pharmacology; D014611:Vaccination
chemical_list: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D016207:Cytokines; C490098:LTF protein, human; D011994:Recombinant Proteins; D007781:Lactoferrin
keywords: BCG; CHO; adjuvant; lactoferrin; tuberculosis